Huseyin ISTANBULLU, Merve SAYLAM, Gulsah BAYRAKTAR, Ismail ÖZTÜRK, Gunes ÇOBAN

Design, synthesis and bioactivity studies of novel triazolopyrimidinone compounds

This study was aimed to develop novel compounds to combat antimicrobial resistance, which is one of the biggest threats to global health. For this purpose, compounds bearing triazolopyrimidinone ring and N-(methylnaphthalene)piperazine (NMP) hybrids were designed and synthesized. Ten new compounds were synthesized and after proving their chemical structures were tested for antimicrobial activity using disk diffusion and microdilution method against Gram-negative bacterial strains (Escherichia coli and Pseudomonas aeruginosa), Gram-positive bacterial strains (Staphylococcus aureus and Enterococcus faecalis) and fungal strains (Candida albicans and Candida parapsilosis). Anti-biofilm activity and ethidium bromide accumulation assay results were also determined for the selected compounds. Among the tested compounds, hybrid compound H5 showed promising activity against E. faecalis with 16-fold potency compared to its precursor, TP5. Additionally, it has statistically significant inhibition of biofilm production at 10 μg/ml dose against E. coli and P. aeruginosa and a decreasing effect on the relative accumulation of ethidium bromide in P. aeruginosa at 100 μg/ml dose (85.07%) after 30 min. 2,5-disubstitued[1,2,4]triazolo[1,5-a]pyrimidinone heterocyclic core structure and its antimicrobial activity are reported to the literature for the first time in this study.

PDF

___

[1] WHO Fact Sheet Antimicrobial Resistance, 2021. https://www.who.int/news-room/factsheets/ detail/antimicrobial-resistance (accessed 03 June 2021)
[2] World Health Organization (2017). Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis. World Health Organization. https://apps.who.int/iris/handle/10665/311820 (accessed 12 June 2021)
[3] Report to the secretary-general of the United Nations (2019). No time to wait: Securing the future from drug-resistant infections; by Interagency Coordination Group on antimicrobial Resistance (IACG), April 2019.
https://www.who.int/docs/default-source/documents/no-time-to-wait-securing-the-future-from-drug-resistantinfections- en.pdfsfvrsn=5b424d7_6 (accessed 12 June 2021)
[4] Parkes AL, Yule IA. Hybrid antibiotics - clinical progress and novel designs. Expert Opin Drug Discov. 2016;11(7):665- 680. [CrossRef]
[5] Li XZ. Impact of Antimicrobial Drug Efflux Pumps on Antimicrobial Discovery and Development (Chapter 28). In: Li XZ., Elkins C., Zgurskaya H. (eds) Efflux-Mediated Antimicrobial Resistance in Bacteria. Adis, Springer International Publishing, Switzerland, 2016, pp.731-753.
[6] Schweizer F, Gorityala, BK, Guchhait G, Yang X, Zhanel GG. Hybrid antibiotics-based adjuvants overcome resistance in Pseudomonas Aeruginosa. WO 2017/027968 A1.
[7] Skepper CK, Moreau RJ, Appleton BA, Benton BM, Drumm JE 3rd, Feng BY, Geng M, Hu C, Li C, Lingel A, Lu Y, Mamo M, Mergo W, Mostafavi M, Rath CM, Steffek M, Takeoka KT, Uehara K, Wang L, Wei JR, Xie L, Xu W, Zhang Q, de Vicente J. Discovery and Optimization of Phosphopantetheine Adenylyltransferase Inhibitors with Gram- Negative Antibacterial Activity. J Med Chem. 2018; 61(8): 3325-3349. [CrossRef]
[8] Chang L, Xiao M, Yang L, Wang S, Wang SQ, Bender A, Hu A, Chen ZS, Yu B, Liu HM. Discovery of a non-toxic [1,2,4]triazolo[1,5-a]pyrimidin-7-one (WS-10) that modulates ABCB1-mediated multidrug resistance (MDR). Bioorg Med Chem. 2018; 26(18): 5006-5017. [CrossRef]
[9] Bedingfield PT, Cowen D, Acklam P, Cunningham F, Parsons MR, McConkey GA, Fishwick CW, Johnson AP. Factors influencing the specificity of inhibitor binding to the human and malaria parasite dihydroorotate dehydrogenases. J Med Chem. 2012; 55(12): 5841-5850. [CrossRef]
[10] Sanchez RM, Erhard K, Hardwicke MA, Lin H, McSurdy-Freed J, Plant R, Raha K, Rominger CM, Schaber MD, Spengler MD, Moore ML, Yu H, Luengo JI, Tedesco R, Rivero RA. Synthesis and structure-activity relationships of 1,2,4-triazolo[1,5-a]pyrimidin-7(3H)-ones as novel series of potent β isoform selective phosphatidylinositol 3-kinase inhibitors. Bioorg Med Chem Lett. 2012; 22(9): 3198-3202. [CrossRef]
[11] Li ZR, Wang S, Yang L, Yuan XH, Suo FZ, Yu B, Liu HM. Experience-based discovery (EBD) of aryl hydrazines as new scaffolds for the development of LSD1/KDM1A inhibitors. Eur J Med Chem. 2019; 166: 432-444. [CrossRef]
[12] Corson TW, Seo SY, Lee B. Ferrochelatase inhibitors and methods of use. WO 2019/213076 A1.
[13] Shipps Jr GW, Cheng CC, Huang X, Achab A, Orth P, Voigt JH. Inhibitors of Fatty Acid Binding Protein (FABP). US 2012/0190696 A1.
[14] Pinherio S, Pinherio EMC, Muri EMF, Pessoa JC, Cadorini MA, Greco SJ. Biological activities of [1,2,4]triazolo[1,5- a]pyrimidines and analogs. Med Chem Res. 2020; 29: 1751-1776. [CrossRef]
[15] Abdelghani E, Said SA, Assy MG, Abdelhamid AM. Synthesis and antimicrobial evaluation of some new pyrimidines and condensed pyrimidines. Arab J Chem. 2017; 10: S2926-2933. [CrossRef]
[16] Bohnert JA, Kern WV. Selected arylpiperazines are capable of reversing multidrug resistance in Escherichia coli overexpressing RND efflux pumps. Antimicrob Agents Chemother. 2005; 49(2): 849-852. [CrossRef]
[17] Kern WV, Steinke P, Schumacher A, Schuster S, von Baum H, Bohnert JA. Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Escherichia coli. J Antimicrob Chemother. 2006; 57(2): 339-343. [CrossRef]
[18] Schumacher A, Steinke P, Bohnert JA, Akova M, Jonas D, Kern WV. Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Enterobacteriaceae other than Escherichia coli. J Antimicrob Chemother. 2006; 57(2): 344-348. [CrossRef]
[19] Pannek S, Higgins PG, Steinke P, Jonas D, Akova M, Bohnert JA, Seifert H, Kern WV. Multidrug efflux inhibition in Acinetobacter baumannii: comparison between 1-(1-naphthylmethyl)-piperazine and phenyl-arginine-bnaphthylamide. J of Antimicrobial Chemotherapy. 2006; 57(5):970–974. [CrossRef]
[20] Rahman KM, Jamshidi S, Laws MB, Kazi N, Sutton JM, Hind C. Antibiotic Resistance Breakers, WO 2018/220365 A1.
[21] Yang X, Goswami S, Gorityala BK, Domalaon R, Lyu Y, Kumar A, Zhanel GG, Schweizer F. A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria. J Med Chem. 2017; 60(9): 3913-3932. [CrossRef]
[22] Kakwani MD, Palsule Desai NH, Lele AC, Ray M, Rajan MG, Degani MS. Synthesis and preliminary biological evaluation of novel N-(3-aryl-1,2,4-triazol-5-yl) cinnamamide derivatives as potential antimycobacterial agents: an operational Topliss Tree approach. Bioorg Med Chem Lett. 2011; 21(21): 6523-6526. [CrossRef]
[23] Shipps Jr GW, Cheng CC, Huang X, Achab A, Orth P, Voigt JH, Soucy KA. Inhibitors of Fatty Acid Binding Protein (FABP). WO 2010/056631 A1.
[24] Dolzhenko AV, Pastorin G, Dolzhenko AV, Chui WK. An aqueous medium synthesis and tautomerism study of 3(5)- amino-1,2,4-triazoles. Tetrahedron Lett. 2009; 50:2124-2128. [CrossRef]
[25] Reiter J, Pongo L, Somorai T, Pallagi I. On triazoles XIX: The reaction of 5-amino-1, 2, 4-triazoles with functionalized acetoacetic esters. Monatsh Chem. 1990;121(2): 173-187. [CrossRef]
[26] Ships Jr GW, Cheng C, Huang X, Abdelghani A, Orth P, Voigt JH. Inhibitors of Fatty Acid Binding Protein (FABP) WO 2011/043994 A1.
[27] Min J, Guo K, Suryadevara PK, Zhu F, Holbrook G, Chen Y, Feau C, Young BM, Lemoff A, Connelly MC, Kastan MB, Guy RK. Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents. J Med Chem. 2016:28;59(2):559-577. [CrossRef]
[28] Hsu DC, Roth HS, West DC, Botham RC, Novotny CJ, Schmid SC, Hergenrother PJ. Parallel synthesis and biological evaluation of 837 analogues of procaspase-activating compound 1 (PAC-1). ACS Comb Sci. 2012; 14(1): 44-50. [CrossRef]
[29] Silverstein RM, Webster FX, Kiemle DJ (eds). Spectrometric identification of Organic Compounds, 7th ed, John Wiley & Sons Inc., USA, 2005.
30] Ozturk I, Tekintas Y, Temel A, Ermertcan S, Kurutepe S, Hosgor-Limoncu M. In vitro effects of antibiofilm agents and antibiotics on coagulase-negative staphylococci. J Res Pharm. 2020; 24(6): 821-832. [CrossRef]
[31] Stepanovic S, Vukovic D, Dakic I, Savic B, Svabic-Vlahovic M. A modified microtiter-plate test for quantification of staphylococcal biofilm formation. J Microbiol Methods. 2000; 40(2): 175-179. [CrossRef]
[32] Brown AR, Ettefagh KA, Todd D, Cole PS, Egan JM, Foil DH, Graf TN, Schindler BD, Kaatz GW, Cech NB. A mass spectrometry-based assay for improved quantitative measurements of efflux pump inhibition. PLoS One. 2015; 10(5): e0124814. [CrossRef]